Please login to the form below
Ignyta
This page shows the latest Ignyta news and features for those working in and with pharma, biotech and healthcare.
Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review
Roche acquired rights to entrectinib when it bought Ignyta for $1.7bn just over a year ago, having licensed rights to the drug in a $1.55bn deal a few weeks
Latest news
-
Loxo, Bayer get FDA okay for biomarker-driven cancer drug
year. Roche acquired the drug as part of its $1.7bn acquisition of Ignyta last year.
-
A look ahead to key trial readouts at ESMO
new data for Ignyta’s ROS1-targeting entrectinib in solid tumour trial STARTRK-2.
-
Roche buys cancer company Ignyta for $1.7bn
Ignyta is highlighting the ability of its candidate to penetrate the central nervous system, and so tackle cancers that have spread to the brain. ... Once the deal goes through, Ignyta will continue to run the pivotal trial of entrectinib from its
-
Pfizer's SMO inhibitor boosts survival in blood cancer trial
Other SMO inhibitors are also coming through development meanwhile, notably Exelixis/Bristol-Myers Squibb's BMS 833923 - in phase II testing for CML - and Ignyta/ Eli Lilly's taladegib which is
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Pharma deals in March 2015
Two days' later Teva acquired four oncology development programmes (the most advanced in phase I/II) from Ignyta for $42m.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Constellation Pharmaceuticals strengthens management team
Senderowicz has also held roles of increasing responsibility at Ignyta, Tokai Pharmaceuticals and Cerulean Pharma, where he helped secure fast-track designation for the company’s lead clinical development programme in
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
